Phase III Trial Of Dose Escalated Radiation Therapy And Standard Androgen Deprivation Therapy (ADT) With A GNRH Agonist VS. Dose Escalated Radiation Therapy And Enhanced ADT With A GNRH Agonist And TAK-700 For Men With High Risk Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as steroid
17alpha-monooxygenase TAK-700, when used with other hormone therapy, may lessen the amount
of androgens made by the body. Radiation therapy uses high energy x rays to kill tumor
cells. This may be an effective treatment for prostate cancer when combined with hormone
therapy. Studying quality-of-life in patients having cancer treatment may help identify the
intermediate- and long-term effects of treatment on patients with prostate cancer.
PURPOSE: This randomized phase III trial is studying the use of hormone therapy, including
TAK-700, together with radiation therapy in treating patients with prostate cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.